tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Intestinal Volvulus D045822 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Herpes Labialis D006560 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Myelitis D009187 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Watanabe K et al. Fate of long-surviving allografts in tolerant recipients induced by fractionated lymphoid irradiation, donor bone marrow cell infusion, and FK 506 after retransplantation in dogs. 1993 Transplant. Proc. pmid:7679813
Valdivia LA et al. Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. 1993 Transplant. Proc. pmid:7679816
Murase N et al. Effect of FK 506 and antiproliferative agents for heart and liver xenotransplantation from hamster to rat. 1993 Transplant. Proc. pmid:7679817
Schreier MH et al. Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties? 1993 Transplant. Proc. pmid:7679818
Kahan BD Cyclosporine: the base for immunosuppressive therapy--present and future. 1993 Transplant. Proc. pmid:7679819
Fung J et al. Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine. 1993 Transplant. Proc. pmid:7680146
Shibata T et al. Does FK 506 accelerate the development of coronary artery disease in the transplanted heart as well as the native heart? 1993 Transplant. Proc. pmid:7680147
Todo S et al. Intestinal transplantation in humans under FK 506. 1993 Transplant. Proc. pmid:7680148
Reyes J et al. Nutritional management of intestinal transplant recipients. 1993 Transplant. Proc. pmid:7680149
Abu-Elmagd KM et al. Monitoring and treatment of intestinal allograft rejection in humans. 1993 Transplant. Proc. pmid:7680150
McCauley J et al. FK 506 in the management of nephrotic syndrome after renal transplantation. 1993 Transplant. Proc. pmid:7680154
Takahara S et al. [Blood level monitoring of FK506 on kidney transplant recipients]. 1993 Nippon Hinyokika Gakkai Zasshi pmid:7504758
Lieberman I et al. Synergy between tetrandrine and FK506 in prevention of diabetes in BB rats. 1993 Life Sci. pmid:7504774
Müller MK et al. [Pathophysiologic concepts and protective possibilities in experimental pancreatic lesions]. 1993 Z Gastroenterol pmid:7504856
Panis Y and Valleur P [Small intestine transplantation. Experimental and clinical results]. 1993 Ann Chir pmid:7504899
Bruserud O and Pawelec G Cyclosporine A and FK506 show similar immunosuppressive effects on long-term in vitro T-cell proliferation. 1993 Int. J. Immunopharmacol. pmid:7682202
Tsai M et al. Activation of MAP kinases, pp90rsk and pp70-S6 kinases in mouse mast cells by signaling through the c-kit receptor tyrosine kinase or Fc epsilon RI: rapamycin inhibits activation of pp70-S6 kinase and proliferation in mouse mast cells. 1993 Eur. J. Immunol. pmid:7504992
Winkler M et al. Anaemia associated with FK 506 immunosuppression. 1993 Lancet pmid:7682273
Lundemose AG et al. Chlamydia trachomatis Mip-like protein has peptidyl-prolyl cis/trans isomerase activity that is inhibited by FK506 and rapamycin and is implicated in initiation of chlamydial infection. 1993 Mol. Microbiol. pmid:7682281
Wiesner RH et al. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection. 1993 Transplant. Proc. pmid:7682352
Frank B et al. Neurotoxicity of FK 506 in liver transplant recipients. 1993 Transplant. Proc. pmid:7682355
McDiarmid SV et al. FK506 conversion for intractable rejection of the liver allograft. 1993 Transpl. Int. pmid:7507675
Akita K and Mandel TE Effect of FK 506 and anti-CD4 monoclonal antibody treatment on xenografts of organ-cultured fetal pig pancreas and host lymphoid populations. 1993 Transplant. Proc. pmid:7692650
Tokunaga Y et al. Living related liver transplantation across ABO blood groups with FK506 and OKT3. 1993 Transpl. Int. pmid:7507676
Liu J FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. 1993 Trends Pharmacol. Sci. pmid:7692652
David M et al. [Changes in cervix cytology in women with liver transplants treated with immunosuppressive therapy]. 1993 Zentralbl Gynakol pmid:7692689
Wallemacq PE and Reding R FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. 1993 Clin. Chem. pmid:7693372
Nakamura T et al. Protein phosphatase type 2B (calcineurin)-mediated, FK506-sensitive regulation of intracellular ions in yeast is an important determinant for adaptation to high salt stress conditions. 1993 EMBO J. pmid:7693452
Wiederrecht G et al. The mechanism of action of FK-506 and cyclosporin A. 1993 Ann. N. Y. Acad. Sci. pmid:7509138
Morikawa K et al. Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. 1993 Antimicrob. Agents Chemother. pmid:7509146
Schwaninger M et al. The immunosuppressive drugs cyclosporin A and FK506 inhibit calcineurin phosphatase activity and gene transcription mediated through the cAMP-responsive element in a nonimmune cell line. 1993 Naunyn Schmiedebergs Arch. Pharmacol. pmid:7509460
Shapiro R et al. FK 506 interaction with danazol. 1993 Lancet pmid:7684106
Becker JW et al. FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. 1993 J. Biol. Chem. pmid:7684380
Dickey JB et al. Periocular FK-506 delays allograft rejection in rat penetrating keratoplasty. 1993 Cornea pmid:7684663
Francavilla A et al. Hepatic regeneration and growth factors. 1993 J Surg Oncol Suppl pmid:7684910
Connelly PR et al. Probing hydration contributions to the thermodynamics of ligand binding by proteins. Enthalpy and heat capacity changes of tacrolimus and rapamycin binding to FK506 binding protein in D2O and H2O. 1993 Biochemistry pmid:7684925
Thomson AW et al. Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures. 1993 Transpl. Immunol. pmid:7521738
Matsuura T et al. Organ-specific unresponsiveness induced by intrathymic injection of donor bone marrow cells and a short course of immunosuppression in the rat heart transplantation model. 1993 Transpl. Immunol. pmid:7521742
Fujisawa T et al. Dose study of the immunosuppression of FK 506 in canine lung allo-transplantation. 1993 Surg. Today pmid:7686416
Ueno M et al. [Immunosuppressive effect in combination therapy of cyclosporine A, FK506 and 15-deoxyspergualin on a pancreatic islet xenotransplantation]. 1993 Nihon Geka Gakkai Zasshi pmid:7686615
Thomson AW et al. FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh. 1993 Springer Semin. Immunopathol. pmid:7686690
Koga T et al. Pulmonary infiltrates recovered by FK506 in a patient with Behçet's disease. 1993 Chest pmid:7686837
Valdivia LA et al. Dendritic cell replacement in long-surviving liver and cardiac xenografts. 1993 Transplantation pmid:7689265
Odocha O et al. Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7689268
Odocha O et al. Serum cholesterol levels in African Americans after renal transplantation under FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7689269
McCauley J et al. Renal transplantation under FK 506 in African-Americans: early experience. 1993 Transplant. Proc. pmid:7689270
Groth CG et al. New immunosuppressive drugs in transplantation. 1993 Transplant. Proc. pmid:7689274
Olivera DL et al. Divergent effects of rapamycin on mouse and rat cells following mitogenic stimulation. 1993 Clin. Immunol. Immunopathol. pmid:7690317
Whitington PF et al. Orthotopic auxiliary liver transplantation for Crigler-Najjar syndrome type 1. 1993 Lancet pmid:7690444
Takahashi H and Iizuka H Neither cyclosporin A nor FK506 affects adenylate cyclase responses of fetal rat keratinizing epidermal cells (FRSK cells) at concentrations that inhibit thymidine incorporation. 1993 J. Dermatol. Sci. pmid:7511000